Table 4.
Tumor characteristics at diagnosis according to pathological complete response
| pCRa | Non-pCR | ||
|---|---|---|---|
| Number of patients | 57 | 245 | |
| Estrogen receptor status | positive | 18 (31.6) | 165 (67.3) |
| negative | 38 (66.7) | 72 (29.4) | |
| missing | 1 (1.8) | 8 (3.3) | |
| Progesterone receptor status | positive | 12 (21.1) | 128 (52.2) |
| negative | 44 (77.2) | 109 (44.5) | |
| missing | 1 (1.8) | 8 (3.3) | |
| HER2 status | positive | 35 (61.4) | 60 (24.5) |
| negative | 20 (35.1) | 171 (69.8) | |
| missing | 2 (3.5) | 14 (5.7) | |
| Ki67 | > 20% (high) | 44 (77.2) | 161 (65.7) |
| <=20% (low) | 3 (5.3) | 36 (14.7) | |
| missing | 10 (17.5) | 48 (19.6) | |
| Axillary lymph node | positive FNAb | 41 (71.9) | 156 (63.7) |
| negative FNA | 3 (5.3) | 19 (7.8) | |
| inconclusive FNA | 5 (2.0) | ||
| no FNA | 13 (22.8) | 64 (26.1) | |
| missing | 1 (0.4) | ||
| Tumor size at diagnosis (mm)c | median (IQR) | 28 (20–35) | 35 (25–46) |
apathological complete response
bfine needle aspiration
cMeasured in mammograms or in ultrasound images. When both methods were conclusive an average measure was used